Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...

Drug toxicity: Idiosyncratic Reactions

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...

Drug Toxicity: Dose-Dependent Reactions

Drug Toxicity: Dose-Dependent Reactions

Drug toxicities can be stratified into pharmacological, pathological, or genotoxic based on their mechanisms. The incidence and severity of these toxicities generally increase with the drug's concentration in the body and exposure time.Pharmacological toxicity is evident when the therapeutic effects of drugs overshoot into adverse reactions in a predictable, dose-dependent manner. Central nervous system (CNS) depression from barbiturates is a classic example, with effects escalating from...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Adaptive Decision-Making Under Pressure: Effects of Control Mode-Cognitive Resource Alignment on Performance Within the Contextual Control Model.

Human factors·2026

Same author

Mitigating inadvertent transitions from visual flight rules to instrument meteorological conditions in general aviation: decision-making strategies, cognitive challenges, and training Implications from an applied cognitive task analysis.

Ergonomics·2026

Same author

Development and validation of an algorithm for identifying patients undergoing dialysis from patients with advanced chronic kidney disease.

Clinical and experimental nephrology·2025

Same author

Factors associated with awareness of chronic kidney disease, and impact of awareness on renal prognosis.

Clinical and experimental nephrology·2024

Same author

Metabolomic analysis of serum samples from a clinical study on ipragliflozin and metformin treatment in Japanese patients with type 2 diabetes: Exploring human metabolites associated with visceral fat reduction.

Pharmacotherapy·2023

Same author

Low dose red yeast rice with monacolin K lowers LDL cholesterol and blood pressure in Japanese with mild dyslipidemia: A multicenter, randomized trial.

Asia Pacific journal of clinical nutrition·2021

Search research articles

Related Experiment Video

Updated: Jun 10, 2026

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

Drug-induced liver disease.

Jiwon W Kim¹, Akiko Hattori, Paula V Phongsamran

¹Department of Clinical Pharmacy and Pharmaceutical Economics and Policy, University of Southern California School of Pharmacy, USC University Hospital, 1500 San Pablo Street, Los Angeles, CA 90033, USA. jiwonkim@usc.edu

Critical Care Nursing Clinics of North America

|August 10, 2010

Summary

Drug-induced liver injury (DILI) affects over 1000 medications, presenting as acute or chronic liver disease. Early recognition and avoidance of the offending drug are crucial for managing DILI, as diagnostic tools are limited.

More Related Videos

Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms

Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms

Published on: May 29, 2020

The Dimethylnitrosamine Induced Liver Fibrosis Model in the Rat

The Dimethylnitrosamine Induced Liver Fibrosis Model in the Rat

Published on: June 17, 2016

Related Experiment Videos

Last Updated: Jun 10, 2026

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms

Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms

Published on: May 29, 2020

The Dimethylnitrosamine Induced Liver Fibrosis Model in the Rat

The Dimethylnitrosamine Induced Liver Fibrosis Model in the Rat

Published on: June 17, 2016

Area of Science:

Hepatology
Clinical Pharmacology
Toxicology

Background:

Over 1000 drugs are linked to liver injury, manifesting as diverse forms of acute and chronic liver disease.
Drug-induced liver disease (DILI) poses a significant challenge to healthcare professionals due to diagnostic complexities.
Current assessment tools for DILI lack the reliability and practicality needed for effective diagnosis.

Purpose of the Study:

To highlight the challenges in identifying and preventing drug-induced liver disease.
To emphasize the need for improved diagnostic methods for DILI.
To underscore the importance of early recognition and avoidance of causative agents in managing DILI.

Main Methods:

Review of existing literature on drug-induced liver injury.
Analysis of clinical presentations and outcomes of DILI.
Discussion of current diagnostic limitations and management strategies.

Main Results:

Drug-induced liver injury encompasses a wide spectrum of liver damage associated with numerous medications.
The absence of reliable diagnostic tools complicates the identification of DILI.
Supportive care is the primary management approach, with avoidance of the causative agent being key.

Conclusions:

Drug-induced liver disease is a common and challenging clinical problem.
Effective management hinges on timely recognition and withdrawal of the implicated drug.
Further development of practical diagnostic tools for DILI is warranted.